

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



August 20, 2026

Company name: TAUNS Laboratories, Inc.
Representative: Masaki Nonaka, President and CEO
(Code no.: 197A, Standard Market, Tokyo Stock Exchange)
Contact person: Yoshio Uchiyama, Director and CFO
Tel: +81-55-953-9590

Notice Concerning Capital and Business Alliance with Asia Pathogenomics Co., Ltd.

TAUNS Laboratories, Inc. (headquartered in Izunokuni-shi, Shizuoka, Japan; Masaki Nonaka, President and CEO; Securities Code: 197A; hereinafter “the Company”) hereby announces that it has subscribed for common shares issued by Asia Pathogenomics Co., Ltd. (headquartered in New Taipei City, Taiwan; LIU, CHUN-HAO, President and CEO; hereinafter “APG”). In addition, the Company and APG have reached a basic agreement to jointly develop and promote a metagenomic next-generation sequencing (mNGS) business for infectious diseases in Japan. The parties have also agreed to expand next-generation sequencing (NGS) testing capabilities at the Company's testing center, “TAUNS Clinical Laboratory.”¹

1. Background and Purpose of the Alliance

APG provides highly accurate infectious disease testing services using metagenomic next-generation sequencing (mNGS) technology, which comprehensively detects pathogen genetic material present in patient specimens. The test results are analyzed using APG's proprietary pathogen analysis platform and region-specific pathogen genome databases. APG is currently the only company that has successfully commercialized an infectious disease mNGS service in Taiwan with regulatory approval from the Taiwanese government.

Under its Med-Term Management Plan, TAUNS has positioned contract testing services as one of its new testing platforms and is advancing the provision of multi-omics contract testing services by introducing state-of-the-art testing equipment at TAUNS Clinical Laboratory.

¹ NGS (Next-Generation Sequencing) is a high-throughput method for rapidly analyzing DNA nucleotide sequences. Unlike conventional Sanger sequencing, which analyzes a single DNA fragment sequentially, NGS can simultaneously analyze millions of DNA fragments in parallel, enabling the generation of vast amounts of genetic data in a relatively short period of time. NGS is expected to play an increasingly important role across a wide range of fields, including cancer genomics, research on hereditary diseases, infectious disease diagnostics, precision medicine, and biomarker discovery, by providing comprehensive and highly efficient genetic analysis.

Through this collaboration, TAUNS aims to accelerate the development of a next-generation contract testing service platform by leveraging APG's technology, expertise, and proven track record. By doing so, we seek to contribute to addressing societal challenges through the delivery of innovative diagnostic solutions.

2. Overview of Asia Pathogenomics Co., Ltd.

(1) Name	Asia Pathogenomics Co., Ltd.
(2) Address	Unit 12, F.9, No.93, Sec.1, Xintai 5th Rd., Xizhi Dist., New Taipei City, Taiwan (R.O.C) 221
(3) Title and name of representative	LIU, CHUN-HAO, President and CEO
(4) Business	Pathogen Testing Services
(5) Date of establishment	January 7, 2020
(6) Corporate site	https://www.asiopathogenomics.com/

3. Comments from Both Companies

Comment from Masaki Nonaka, President and CEO, TAUNS Laboratories, Inc.

As Japan's population continues to age and demand for healthcare services increases, the efficient utilization of limited healthcare resources has become increasingly important. In this environment, the role of diagnostic technologies is becoming more critical than ever.

Under our Med-Term Management Plan, we have established the vision of "Solving social issues with diagnostic technology, data, and AI." By integrating advanced diagnostic technologies with data analytics and artificial intelligence, we aim to create innovative testing solutions and contribute to the optimization of diagnostic workflows across the healthcare system.

The expansion of our NGS testing capabilities represents one of our key strategic initiatives. In particular, APG's mNGS technology is an advanced platform that enables comprehensive analysis of pathogen genetic material in clinical specimens, providing highly accurate infectious disease testing while minimizing the risk of missed pathogen detection.

APG is an important partner with outstanding expertise and a proven track record in the field of next-generation sequencing. We are delighted to have entered into this business alliance with APG.

Through this collaboration, we look forward to contributing to the further advancement of infectious disease diagnostic workflows in Japan and to improving the quality and efficiency of healthcare delivery.

Comment from LIU, CHUN-HAO, President and CEO, Asia Pathogenomics Co., Ltd.

We are honored to establish this capital and business alliance with TAUNS Laboratories. From our very first discussions, we recognized a shared vision for advancing diagnostic medicine and creating long-term value through innovation.

We have been deeply impressed by TAUNS' clear vision, strong leadership, and commitment to embracing new technologies. We look forward to sharing APG's experience and practical expertise in next-generation sequencing, bioinformatics, and pathogen genomics, while working together to establish a strong foundation for future NGS capabilities.

We believe this alliance marks the beginning of a long-term collaboration. By combining our respective strengths and working together with clinical and industry partners in Japan, we hope to create broader opportunities for future collaboration and innovation, including the advancement of next-generation infectious disease diagnostics, ultimately contributing to better patient care.

4. Outlook

At present, the Company expects that this basic agreement will have only a limited impact on its near-term financial performance. Should any material impact become apparent, the Company will promptly disclose such information.

5. Other Matters

Certain details regarding this basic agreement have not been disclosed based on mutual agreement between the parties.